Thursday, October 2, 2008

Baxter's Antimicrobial IV Technology Now Shown to Kill Six Common Pathogens, Including MRSA and VRE

Baxter Healthcare Corporation today announced that it received 510(k) clearance for expanded labeling for the first antimicrobial needleless intravenous (IV) connector, V-Link Luer-activated device (LAD) with VitalShield protective coating. With a new federal policy restricting reimbursement for healthcare-associated infections (HAIs) taking effect on October 1, healthcare professionals are seeking effective techniques and technologies to reduce the risk of contamination from a broad array of pathogens (infection-causing agents) within their hospitals.

The details can be read here.

No comments: